MLchartDataset catalogue

Brivanib alaninate

Term · Oncology and biomedicine · MLC-T-ONC-001254

  1. A substance being studied in the treatment of cancer. Brivanib alaninate may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor 2 inhibitor and a type of antiangiogenesis agent.

  2. The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression.

Table 1. Record
IdentifierMLC-T-ONC-001254
FieldOncology and biomedicine
ReferencesNCI Dictionary of Cancer Terms; National Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-001254",
  "term": "Brivanib alaninate",
  "field": "Oncology and biomedicine",
  "definitions": [
    "A substance being studied in the treatment of cancer. Brivanib alaninate may prevent the growth of new blood vessels that tumors need to grow and may kill cancer cells. It is a type of vascular endothelial growth factor receptor 2 inhibitor and a type of antiangiogenesis agent.",
    "The alaninate salt of a vascular endothelial growth factor receptor 2 (VEGFR2) inhibitor with potential antineoplastic activity. Brivanib strongly binds to and inhibits VEGFR2, a tyrosine kinase receptor expressed almost exclusively on vascular endothelial cells; inhibition of VEGFR2 may result in inhibition of tumor angiogenesis, inhibition of tumor cell growth, and tumor regression."
  ],
  "references": [
    "NCI Dictionary of Cancer Terms",
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/brivanib-alaninate/"
}

Record 3,867 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.